NCT07117760View on ClinicalTrials.gov

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Prostate Cancer
Interventions
DRUG

225Ac-LNC1011

administered intravenously once every 8-10 weeks (1 cycle) for 4 cycles

DRUG

68Ga-PSMA-11

Intravenous dose of approx. 150 MBq at screening and at time of centrally confirmed radiographic progressive disease

Trial Locations (1)

350005

RECRUITING

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER